FXR：NASH 和纤维化疾病的结构、生物学和药物研发。
FXR: structures, biology, and drug development for NASH and fibrosis diseases.
机构信息
The State Key Laboratory of Cellular Stress Biology, Innovation Center for Cell Signaling Network, School of Life Sciences, Xiamen University, Xiamen, 361005, China.
出版信息
Acta Pharmacol Sin. 2022 May;43(5):1120-1132. doi: 10.1038/s41401-021-00849-4. Epub 2022 Feb 25.
Abstract
The nuclear receptor farnesoid-X-receptor (FXR) plays an essential role in bile acid, glucose, and lipid homeostasis. In the last two decades, several diseases, such as obesity, type 2 diabetes, nonalcoholic fatty liver disease, cholestasis, and chronic inflammatory diseases of the liver and intestine, have been revealed to be associated with alterations in FXR functions. FXR has become a promising therapeutic drug target, particularly for enterohepatic diseases. Despite the large number of FXR modulators reported, only obeticholic acid (OCA) has been approved for primary biliary cholangitis (PBC) therapy as FXR modulator. In this review, we summarize the structure and function of FXR, the development of FXR modulators, and the structure-activity relationships of FXR modulators. Based on the structural analysis, we discuss potential strategies for developing future therapeutic FXR modulators to overcome current limitations, providing new perspectives for enterohepatic and metabolic diseases treatment.
摘要
核受体法尼醇 X 受体（FXR）在胆汁酸、葡萄糖和脂质稳态中发挥着重要作用。在过去的二十年中，几种疾病，如肥胖症、2 型糖尿病、非酒精性脂肪性肝病、胆汁淤积、以及肝和肠的慢性炎症性疾病，都被揭示与 FXR 功能的改变有关。FXR 已成为一种有前途的治疗药物靶点，特别是针对肝胆疾病。尽管已经报道了大量的 FXR 调节剂，但只有奥贝胆酸（OCA）被批准作为 FXR 调节剂用于原发性胆汁性胆管炎（PBC）的治疗。在这篇综述中，我们总结了 FXR 的结构和功能、FXR 调节剂的发展以及 FXR 调节剂的构效关系。基于结构分析，我们讨论了开发未来治疗性 FXR 调节剂的潜在策略，以克服当前的限制，为肝胆和代谢性疾病的治疗提供新的视角。
相似文献
1
FXR: structures, biology, and drug development for NASH and fibrosis diseases.FXR：NASH 和纤维化疾病的结构、生物学和药物研发。
Acta Pharmacol Sin. 2022 May;43(5):1120-1132. doi: 10.1038/s41401-021-00849-4. Epub 2022 Feb 25.
2
Obeticholic acid-a new therapy in PBC and NASH.奥贝胆酸——治疗 PBC 和 NASH 的新疗法。
Br Med Bull. 2020 May 15;133(1):95-104. doi: 10.1093/bmb/ldaa006.
3
The regulation of tissue-specific farnesoid X receptor on genes and diseases involved in bile acid homeostasis.组织特异性法尼醇 X 受体对胆汁酸动态平衡相关基因和疾病的调控。
Biomed Pharmacother. 2023 Dec;168:115606. doi: 10.1016/j.biopha.2023.115606. Epub 2023 Oct 7.
4
Enterohepatic and non-canonical roles of farnesoid X receptor in controlling lipid and glucose metabolism.法尼醇 X 受体在脂质和葡萄糖代谢调控中的肠肝及非经典作用。
Mol Cell Endocrinol. 2022 Jun 1;549:111616. doi: 10.1016/j.mce.2022.111616. Epub 2022 Mar 15.
5
Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease.胆汁酸及其受体：非酒精性脂肪性肝病的生物学与药物研发
Acta Pharmacol Sin. 2022 May;43(5):1103-1119. doi: 10.1038/s41401-022-00880-z. Epub 2022 Feb 25.
6
Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH).用于治疗非酒精性脂肪性肝炎 (NASH) 的胆汁酸调节剂。
Expert Opin Investig Drugs. 2020 Jun;29(6):623-632. doi: 10.1080/13543784.2020.1763302. Epub 2020 Jun 19.
7
Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid.人精准切肝片中受 FXR 激动剂奥贝胆酸刺激的基因表达谱
J Hepatol. 2016 May;64(5):1158-1166. doi: 10.1016/j.jhep.2016.01.016. Epub 2016 Jan 23.
8
Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.法尼醇 X 受体激动剂奥贝胆酸治疗 2 型糖尿病合并非酒精性脂肪性肝病患者的疗效和安全性。
Gastroenterology. 2013 Sep;145(3):574-82.e1. doi: 10.1053/j.gastro.2013.05.042. Epub 2013 May 30.
9
Farnesoid X receptor modulators 2014-present: a patent review.法尼醇 X 受体调节剂 2014 年至今：专利研究综述。
Expert Opin Ther Pat. 2018 May;28(5):351-364. doi: 10.1080/13543776.2018.1459569. Epub 2018 Apr 13.
10
FXR modulators for enterohepatic and metabolic diseases.法尼醇 X 受体调节剂在肝胆和代谢疾病中的应用。
Expert Opin Ther Pat. 2018 Nov;28(11):765-782. doi: 10.1080/13543776.2018.1527906. Epub 2018 Oct 8.
引用本文的文献
1
Research progress and perspectives of non-coding RNAs in primary biliary cholangitis: from mechanisms to therapeutics.非编码RNA在原发性胆汁性胆管炎中的研究进展与展望：从机制到治疗
Front Med (Lausanne). 2025 Aug 4;12:1611640. doi: 10.3389/fmed.2025.1611640. eCollection 2025.
2
From Nuclear Receptor Regulation to Spleen Activating and Accumulation Resolving Therapy: A Review of Traditional Chinese Medicine Against Diabetes and Inflammation.从核受体调节到健脾消积疗法：中医药治疗糖尿病与炎症的综述
Int J Mol Sci. 2025 Jun 30;26(13):6345. doi: 10.3390/ijms26136345.
3
Advances of exosome regulating‑FXR to repair inflammatory bowel disease (Review).外泌体调节法尼醇X受体修复炎症性肠病的研究进展（综述）
Int J Mol Med. 2025 Sep;56(3). doi: 10.3892/ijmm.2025.5576. Epub 2025 Jul 4.
4
Orchestration of Gut-Liver-Associated Transcription Factors in MAFLD: From Cross-Organ Interactions to Therapeutic Innovation.非酒精性脂肪性肝病中肠道-肝脏相关转录因子的调控：从跨器官相互作用到治疗创新
Biomedicines. 2025 Jun 10;13(6):1422. doi: 10.3390/biomedicines13061422.
5
Farnesoid X receptor‑driven metabolic plasticity: Bridging physiological adaptation and malignant transformation in lipid handling (Review).法尼醇X受体驱动的代谢可塑性：连接脂质代谢中的生理适应与恶性转化（综述）
Int J Mol Med. 2025 Jul;56(1). doi: 10.3892/ijmm.2025.5551. Epub 2025 May 16.
6
Prunellate A: An Unprecedented Lignan Lactone with a 6/7/6/5-Fused Tetracycle Skeleton by C-2-C-2' and C-7-C-8' Linkage from the Chinese Medicinal Plant Inhibiting the Activation of Hepatic Stellate Cells by Targeting FXR.夏枯草素A：一种来自中国药用植物的前所未有的木脂素内酯，具有通过C-2-C-2'和C-7-C-8'连接的6/7/6/5稠合四环骨架，通过靶向法尼醇X受体抑制肝星状细胞的激活。
ACS Omega. 2025 Mar 20;10(12):12425-12431. doi: 10.1021/acsomega.4c11609. eCollection 2025 Apr 1.
7
27-Hydroxymangiferolic Acid Extends Lifespan and Improves Neurodegeneration in by Activating Nuclear Receptors.27-羟基芒果甾酸通过激活核受体延长寿命并改善[具体生物名称缺失]中的神经退行性变。
Molecules. 2025 Feb 21;30(5):1010. doi: 10.3390/molecules30051010.
8
Xiaohua Funing decoction ameliorates non-alcoholic fatty liver disease by modulating the gut microbiota and bile acids.小华复宁汤通过调节肠道微生物群和胆汁酸改善非酒精性脂肪性肝病。
Front Microbiol. 2025 Feb 10;16:1511885. doi: 10.3389/fmicb.2025.1511885. eCollection 2025.
9
Tenascin C-Guided Nanosystem for Precision Delivery of Obeticholic Acid in Liver Fibrosis Therapy.用于肝纤维化治疗中精准递送奥贝胆酸的肌腱蛋白C引导纳米系统
Pharmaceutics. 2024 Dec 28;17(1):32. doi: 10.3390/pharmaceutics17010032.
10
Current Treatment Regimens and Promising Molecular Therapies for Chronic Hepatobiliary Diseases.慢性肝胆疾病的当前治疗方案及有前景的分子疗法
Biomolecules. 2025 Jan 14;15(1):121. doi: 10.3390/biom15010121.
本文引用的文献
1
Safety, Pharmacokinetics, Pharmacodynamics, and Formulation of Liver-Distributed Farnesoid X-Receptor Agonist TERN-101 in Healthy Volunteers.健康志愿者中肝分布法尼醇 X 受体激动剂 TERN-101 的安全性、药代动力学、药效学和制剂研究。
Clin Pharmacol Drug Dev. 2021 Oct;10(10):1198-1208. doi: 10.1002/cpdd.960. Epub 2021 Jul 24.
2
Farnesoid X receptor (FXR): Structures and ligands.法尼酯X受体（FXR）：结构与配体
Comput Struct Biotechnol J. 2021 Apr 20;19:2148-2159. doi: 10.1016/j.csbj.2021.04.029. eCollection 2021.
3
Drugs for Non-alcoholic Steatohepatitis (NASH): Quest for the Holy Grail.用于非酒精性脂肪性肝炎（NASH）的药物：对圣杯的探寻。
J Clin Transl Hepatol. 2021 Feb 28;9(1):40-50. doi: 10.14218/JCTH.2020.00055. Epub 2020 Dec 9.
4
A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis.一种结构优化的 FXR 激动剂，MET409，可在 12 周内降低非酒精性脂肪性肝炎患者的肝脏脂肪含量。
J Hepatol. 2021 Jul;75(1):25-33. doi: 10.1016/j.jhep.2021.01.047. Epub 2021 Feb 11.
5
Intestine-specific FXR agonists as potential therapeutic agents for colorectal cancer.肠特异性 FXR 激动剂作为结直肠癌的潜在治疗药物。
Biochem Pharmacol. 2021 Apr;186:114430. doi: 10.1016/j.bcp.2021.114430. Epub 2021 Feb 6.
6
Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH.用于桥接 NASH 所致纤维化和肝硬化的 cilofexor 和 firsocostat 联合治疗。
Hepatology. 2021 Feb;73(2):625-643. doi: 10.1002/hep.31622.
7
Structural basis of tropifexor as a potent and selective agonist of farnesoid X receptor.作为法尼醇 X 受体的一种有效和选择性激动剂，曲匹非格的结构基础。
Biochem Biophys Res Commun. 2021 Jan 1;534:1047-1052. doi: 10.1016/j.bbrc.2020.10.039. Epub 2020 Oct 26.
8
Emerging drugs for the treatment of non-alcoholic steatohepatitis: a focused review of farnesoid X receptor agonists.治疗非酒精性脂肪性肝炎的新兴药物：法尼醇 X 受体激动剂的重点综述。
Expert Opin Emerg Drugs. 2020 Sep;25(3):251-260. doi: 10.1080/14728214.2020.1796968. Epub 2020 Aug 12.
9
Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH).用于治疗非酒精性脂肪性肝炎 (NASH) 的胆汁酸调节剂。
Expert Opin Investig Drugs. 2020 Jun;29(6):623-632. doi: 10.1080/13543784.2020.1763302. Epub 2020 Jun 19.
10
Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial.西罗法辛，一种非甾体 FXR 激动剂，在非肝硬化 NASH 患者中的应用：一项 2 期随机对照试验。
Hepatology. 2020 Jul;72(1):58-71. doi: 10.1002/hep.31205.
Zotero 插件